Please assess the completion status of the following clinical trial:

Trial Title: Trientine Hydrochloride for the Prevention of Macular Edema Associated With Pan-retinal Photocoagulation for Severe Non-proliferative and Proliferative Diabetic Retinopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Severe non-proliferative diabetic retinopathy or retinal neovascularization secondary to diabetic retinopathy meeting DRS criteria for PRP laser~* ETDRS (Early treatment of Diabetic Retinopathy Study) eye score of at least 34-73 letters (at 2 meters) (20/20 to 20/320) for study eye and 20/800 in non-study eye~* Clinical evidence of macular microantiopathy in the study eye (lipid or retinal thickness is acceptable)~* No other ocular disease that could be responsible for decreased vision, macular edema or could limit macular imaging~Exclusion Criteria:~* Individuals with retinal neovascularization from causes other than diabetic retinopathy~* Any intraocular surgery within 2 months or Yag capsulotomy within 1 month in the study eye~* Prior retinal or vitreous surgery (including posterior segment vitrectomy or scleral buckling)~* Medical conditions requiring the use of mineral supplements (copper in particular)~* Individuals with anemia~* Individuals with mental or physical disabilities that prevent accurate vision testing~* History of treatment of PDR by PRP~* Active hepatitis, clinically significant liver disease or any evidence of renal failure.~* Stroke or myocardial infarction within preceding 6 months or ventricular tachycardia under treatment~* History of severe cardiac disease or unstable angina~* Subjects who are in an experimental therapy study or who have received experimental therapy within the last 12 weeks~* Subjects who are a poor medical risk because of other systemic diseases or active uncontrolled infections~* Women of childbearing potential not on 2 effective forms of birth control~* Women who are pregnant or plan to become pregnant~* Subjects with an allergy to fluorescein dye.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Arm II (Type: EXPERIMENTAL): None
- Arm I. Placebo + Pan-Retinal Photocoagulation (Type: PLACEBO_COMPARATOR): All participating subjects will all receive PRP (pan-retinal photocoagulation) according to present standards of care; however, subjects randomized the placebo group will be on a 10-day course of oral placebo capsules at 1500mg administered for 7-days prior to and 3 days after the PRP sessions.

Based on this trial design, predict the completion outcome and termination type (if applicable).